CHICAGO (March 26, 2008)- GE Healthcare Financial Services has provided a $15 million senior secured credit facility to CryoLife, Inc., a biomaterials, medical device and tissue processing company based in Kennesaw, GA. CryoLife will use the debt financing for working capital, acquisitions and other corporate purposes.

"GE Healthcare Financial Services was able to understand our needs and provide the financing solution we were seeking," said Steven G. Anderson, Chairman, Chief Executive Officer and President of CryoLife. "Their team of financial experts offered certainty of execution in a turbulent market and delivered the transaction in a quick and efficient manner."

"We are extremely pleased to add CryoLife as a new customer," said Robert McCarrick, Senior Managing Director of Corporate Finance for GE Healthcare Financial Services."Our financing expertise and strong balance sheet enabled us to quickly underwrite this transaction and will help CryoLife achieve its short- and long-term financing needs."

A leader in corporate finance, GE ranks at the top of several leveraged lending league tables from the Loan Pricing Corporation for 2007, including:

• #2 US Highly Leveraged Lead Arranger

• #4 US Second Lien Lead Arranger

• #4 US Healthcare Lead Arranger

GE Healthcare Financial Services is the premier provider of capital, financial solutions, and related services for the global healthcare market. With approximately $21 billion in assets, GE Healthcare Financial Services offers a full range of financing capabilities from equipment leasing and real estate financing to working capital lending, vendor programs, and acquisition financing. With a dedicated focus and a deep knowledge of the healthcare industry, GE Healthcare Financial Services collaborates with customers to create tailored financial solutions that help them improve their productivity and profitability. For more information, visit www.gehealthcarefinance.com.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for its CryoValve® SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft® Technology. The Company's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien® stentless porcine heart valve, which is CE marked for distribution within the European Community.

Media Contacts

Deia Campanelli
GE Healthcare Financial Services
312-441-6169
deia.campanelli@ge.com